BR112019008374A2 - inibidor seletivo de egfr mutante por inserção do éxon 20 - Google Patents
inibidor seletivo de egfr mutante por inserção do éxon 20Info
- Publication number
- BR112019008374A2 BR112019008374A2 BR112019008374A BR112019008374A BR112019008374A2 BR 112019008374 A2 BR112019008374 A2 BR 112019008374A2 BR 112019008374 A BR112019008374 A BR 112019008374A BR 112019008374 A BR112019008374 A BR 112019008374A BR 112019008374 A2 BR112019008374 A2 BR 112019008374A2
- Authority
- BR
- Brazil
- Prior art keywords
- egfr inhibitor
- mutant egfr
- selective exon
- insert mutant
- exon insert
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
agente antitumoral compreendendo um composto selecionado do grupo consistindo nos compostos a a d descritos na descrição, ou um sal dos mesmos, para tratar um paciente com tumor maligno que expressa egfr tendo mutação por inserção do éxon 20.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016213072 | 2016-10-31 | ||
| PCT/JP2017/037186 WO2018079310A1 (ja) | 2016-10-31 | 2017-10-13 | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008374A2 true BR112019008374A2 (pt) | 2019-10-01 |
Family
ID=62024991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008374A BR112019008374A2 (pt) | 2016-10-31 | 2017-10-13 | inibidor seletivo de egfr mutante por inserção do éxon 20 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11857513B2 (pt) |
| EP (1) | EP3533449B1 (pt) |
| JP (1) | JP6896755B2 (pt) |
| KR (1) | KR102639585B1 (pt) |
| CN (1) | CN110191711B (pt) |
| AU (1) | AU2017350440B2 (pt) |
| BR (1) | BR112019008374A2 (pt) |
| CA (1) | CA3041015A1 (pt) |
| DK (1) | DK3533449T3 (pt) |
| ES (1) | ES2955832T3 (pt) |
| FI (1) | FI3533449T3 (pt) |
| HU (1) | HUE063712T2 (pt) |
| IL (1) | IL266239B2 (pt) |
| JO (1) | JOP20190073A1 (pt) |
| MX (1) | MX2019004969A (pt) |
| PH (1) | PH12019500957A1 (pt) |
| PL (1) | PL3533449T3 (pt) |
| PT (1) | PT3533449T (pt) |
| SG (1) | SG11201903875QA (pt) |
| TW (1) | TWI774699B (pt) |
| WO (1) | WO2018079310A1 (pt) |
| ZA (1) | ZA201902629B (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| US20220072000A1 (en) * | 2018-12-28 | 2022-03-10 | Taiho Pharmaceutical Co., Ltd. | L718 and/or l792 mutant treatment-resistant egfr inhibitor |
| CN113453764B (zh) | 2019-02-15 | 2024-04-16 | 大鹏药品工业株式会社 | 7H-吡咯并[2,3-d]嘧啶-4-胺衍生物 |
| WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
| CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
| WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
| WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| CA2601766A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
| DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
| MY152972A (en) | 2009-07-10 | 2014-12-15 | Taiho Pharmaceutical Co Ltd | Azabicyclo compound and salt thereof |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| MX2013007938A (es) | 2011-01-07 | 2013-11-01 | Taiho Pharmaceutical Co Ltd | Compuesto biciclico novedoso o sal del mismo. |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| JP5557963B2 (ja) * | 2012-02-23 | 2014-07-23 | 大鵬薬品工業株式会社 | キノリルピロロピリミジル縮合環化合物又はその塩 |
| MX2015010934A (es) | 2013-02-22 | 2015-10-29 | Taiho Pharmaceutical Co Ltd | Metodo para producir un compuesto triciclico, y un compuesto triciclico capaz de producirse por dicho metodo de produccion. |
| CA2922077C (en) * | 2013-08-22 | 2018-06-26 | Taiho Pharmaceutical Co., Ltd. | Quinoline-substituted compound |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN110526912B (zh) | 2014-06-19 | 2023-02-14 | 武田药品工业株式会社 | 用于激酶抑制的杂芳基化合物 |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| PT3677266T (pt) | 2017-09-01 | 2024-03-04 | Taiho Pharmaceutical Co Ltd | Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21 |
-
2017
- 2017-06-16 JO JOP/2019/0073A patent/JOP20190073A1/ar unknown
- 2017-10-13 HU HUE17864975A patent/HUE063712T2/hu unknown
- 2017-10-13 IL IL266239A patent/IL266239B2/en unknown
- 2017-10-13 TW TW106135203A patent/TWI774699B/zh active
- 2017-10-13 DK DK17864975.2T patent/DK3533449T3/da active
- 2017-10-13 AU AU2017350440A patent/AU2017350440B2/en active Active
- 2017-10-13 PL PL17864975.2T patent/PL3533449T3/pl unknown
- 2017-10-13 CA CA3041015A patent/CA3041015A1/en active Pending
- 2017-10-13 PT PT178649752T patent/PT3533449T/pt unknown
- 2017-10-13 EP EP17864975.2A patent/EP3533449B1/en active Active
- 2017-10-13 JP JP2018547565A patent/JP6896755B2/ja active Active
- 2017-10-13 BR BR112019008374A patent/BR112019008374A2/pt unknown
- 2017-10-13 KR KR1020197015270A patent/KR102639585B1/ko active IP Right Grant
- 2017-10-13 ES ES17864975T patent/ES2955832T3/es active Active
- 2017-10-13 FI FIEP17864975.2T patent/FI3533449T3/fi active
- 2017-10-13 SG SG11201903875QA patent/SG11201903875QA/en unknown
- 2017-10-13 WO PCT/JP2017/037186 patent/WO2018079310A1/ja unknown
- 2017-10-13 MX MX2019004969A patent/MX2019004969A/es unknown
- 2017-10-13 CN CN201780067762.5A patent/CN110191711B/zh active Active
- 2017-10-31 US US16/345,792 patent/US11857513B2/en active Active
-
2019
- 2019-04-25 ZA ZA2019/02629A patent/ZA201902629B/en unknown
- 2019-04-29 PH PH12019500957A patent/PH12019500957A1/en unknown
-
2023
- 2023-11-17 US US18/512,528 patent/US20240148734A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008374A2 (pt) | inibidor seletivo de egfr mutante por inserção do éxon 20 | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
| CO2017013065A2 (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2) | |
| BR112016027048A8 (pt) | uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo | |
| EA201890957A1 (ru) | Комбинированная терапия для лечения злокачественных опухолей | |
| PH12020552060A1 (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2018001737A (es) | Mecanismo de resistencia a inhibidores de bromodominio bet. | |
| ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| BR112017027277A2 (pt) | ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula? | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| BR112016008901A2 (pt) | Compostos para uso na prevenção e tratamento de doenças neurodegenerativas e da dor. | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| BR112018012126A2 (pt) | ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante? | |
| BR112018011367A2 (pt) | composição de fluidos para tratamento de poços |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |